1. Introduction
===============

HIV-1 infection typically occurs through a single viral variant \[[@B1-viruses-04-02080],[@B2-viruses-04-02080],[@B3-viruses-04-02080],[@B4-viruses-04-02080],[@B5-viruses-04-02080]\], but the initial viral homogeneity is rather transient as the surviving viruses must mutate to evade host immune defenses or to regain fitness lost during adaptation to the immediate past host (the transmission source partner) \[[@B6-viruses-04-02080]\]. At the population level, HIV-1 subtypes responsible for the global AIDS pandemic can vary by geographic region \[[@B7-viruses-04-02080],[@B8-viruses-04-02080]\], while frequent superinfection can generate mosaic viruses (circulating recombinant forms) to promote viral diversity \[[@B8-viruses-04-02080]\]. Understanding the evolution of HIV-1-host interactions requires close attention to both viral and host (immunologic) dynamics \[[@B9-viruses-04-02080]\].

HIV-1 viral load (VL) set-point is a well-studied phenotype tied to virus-host equilibrium, with high set-point VLs translating to rapid disease progression \[[@B10-viruses-04-02080],[@B11-viruses-04-02080],[@B12-viruses-04-02080],[@B13-viruses-04-02080],[@B14-viruses-04-02080],[@B15-viruses-04-02080],[@B16-viruses-04-02080],[@B17-viruses-04-02080]\] and fast transmission to susceptible hosts \[[@B18-viruses-04-02080],[@B19-viruses-04-02080]\]. In many individuals, the viral 'set-point' is reached within weeks of infection \[[@B12-viruses-04-02080],[@B20-viruses-04-02080],[@B21-viruses-04-02080]\], and it can remain relatively steady (±0.5 log~10~ RNA copies/ml) for years during clinical latency \[[@B10-viruses-04-02080]\]. Progression to AIDS is usually accompanied by (i) rising VL, (ii) substantial loss of CD4+ T-cells in peripheral blood, and (iii) risk for opportunistic infections and malignancies. AIDS diagnosis based on \< 200 CD4 cells/mm^3^ of blood and at least one opportunistic infection \[[@B22-viruses-04-02080],[@B23-viruses-04-02080]\] can serve as another important phenotype for measuring the dynamics of host-virus interactions, but it can take close to a decade to develop even during untreated HIV-1 infection. In the era of highly active antiretroviral therapy (HAART), AIDS diagnosis is increasingly rare, so a focus on studying set-point VL as a proxy of viral fitness under specific microenvironment in the host is well justified, especially since many clinical decisions must be made during the early stages of HIV-1 infection \[[@B9-viruses-04-02080],[@B24-viruses-04-02080]\].

![**Selection of recent (post-2010) publications for systematic review**. Two rounds of searches in PubMed yield 2,660 original research articles that contain three key words (HIV, viral load, and host or viral genome). Only 22 of these meet the criteria for full evaluation here (20 in [Table 1](#viruses-04-02080-t001){ref-type="table"} and two in [Table 2](#viruses-04-02080-t002){ref-type="table"}).](viruses-04-02080-g001){#viruses-04-02080-f001}

HIV-1 VL was, in one way or another, a subject in over 2,600 articles published since January 2010 ([Figure 1](#viruses-04-02080-f001){ref-type="fig"}). Our review here intends to highlight recent population-based research on host and viral correlates of HIV-1 VL set-point or its equivalent. For clarity and fair comparisons, studies assessing the relationship between host and/or viral factors on early set-point VL were selected according to two phenotypes, *i.e.;* set-point and chronic VLs as continuous or categorical endpoints. In addition, it was necessary to exclude studies dealing with children or youth (rare) or with small sample sizes (\<100 HAART-naïve subjects). In the end, a total of 22 original research articles remained after four rounds of selection ([Figure 1](#viruses-04-02080-f001){ref-type="fig"}). Interpretation of these recent studies is relatively straightforward when supporting evidence from earlier reports is available.

2. Host Genetics and Set-Point VL
=================================

2.1 Human Leukocyte Antigen (HLA) Class I and Class II Genes as Prominent Factors
---------------------------------------------------------------------------------

HLA molecules mediate immune responses through multiple mechanisms, and their importance to effective immune control of HIV-1 infection has been well publicized in the past two decades \[[@B9-viruses-04-02080],[@B25-viruses-04-02080],[@B26-viruses-04-02080],[@B27-viruses-04-02080]\]. Polymorphisms around the peptide-binding groove of HLA class I (HLA-I) and HLA-II molecules determine the specificity of cytotoxic T-lymphocyte responses (CTLs) and T-helper cell epitopes, respectively \[[@B28-viruses-04-02080]\]. Direct interactions between HLA-I and killer cell immunoglobulin-like receptors (KIRs) can dictate natural killer (NK) cell function \[[@B29-viruses-04-02080]\], which is further regulated by HLA leader peptides loaded to HLA-E \[[@B30-viruses-04-02080],[@B31-viruses-04-02080]\]. These intertwined properties essential to both innate and adaptive immunity inevitably complicate the analysis of individual HLA alleles and certain functionally relevant residues or motifs shared by different alleles.

When individual HLA-I alleles are compared, new findings ([Table 1](#viruses-04-02080-t001){ref-type="table"}) continue to support the notion that *HLA-A* and *HLA-C* alleles are less prominent than *HLA-B* alleles \[[@B32-viruses-04-02080],[@B33-viruses-04-02080],[@B34-viruses-04-02080],[@B35-viruses-04-02080],[@B36-viruses-04-02080]\]. Specifically, studies have readily recognized *HLA-B\*13, B\*14*, *B\*18*, *B\*27*, *B\*35*, *B\*44, B\*45*, *B\*53, B\*57*, *B\*58:01*, *B\*58:02* and *B\*81* as distinct correlates of HIV-1 VL in several cohorts from Africa and North America \[[@B32-viruses-04-02080],[@B33-viruses-04-02080],[@B34-viruses-04-02080],[@B35-viruses-04-02080],[@B36-viruses-04-02080]\]. Evidence for three *HLA-A* alleles (*A\*32*, *A\*36*, and *A\*74*), two *HLA-C* alleles(*C\*08* and *C\*18*), and one combination (*HLA-A\*30+HLA-C\*03*) is rather consistent with earlier observations, with *HLA-A\*74* being favorable (low VL) in native Africans and African-Americans \[[@B34-viruses-04-02080],[@B35-viruses-04-02080],[@B37-viruses-04-02080],[@B38-viruses-04-02080],[@B39-viruses-04-02080]\]. Linkage disequilibrium (LD) between *HLA-A\*74* and *HLA-B\*57* may obscure the analysis of the former, but an independent contribution by *A\*74* was evident in a large sample size \[[@B39-viruses-04-02080]\]. *HLA-C\*18* as a favorable allele needs further assessment, as it apparently tags two favorable *HLA-B* alleles, *B\*57:03* and *B\*81:01* \[[@B34-viruses-04-02080],[@B40-viruses-04-02080]\]. The *HLA-C\*12---HLA-B\*39* haplotype is another example of neighboring alleles that are hard to separate \[[@B33-viruses-04-02080],[@B35-viruses-04-02080]\].

For HLA-II ([Table 1](#viruses-04-02080-t001){ref-type="table"}), only two alleles have shown appreciable impact on set-point VL: *HLA-DRB1\*01:02* and *HLA-DRB1\*13:03* are associated with relatively high and low VL, respectively \[[@B34-viruses-04-02080],[@B41-viruses-04-02080]\]. Of note, *HLA-DRB1\*01:02* was associated with high VL in a combined cohort of seroconverting patients (SCs) and seroprevalent patients (SPs) or in SPs alone \[[@B34-viruses-04-02080]\]. In theory, SCs are more suitable for association analyses as few viral mutations are seen in early infection when set-point VL is measured. The relatively late effect of *HLA-DRB1\*01:02* (if confirmed) may reflect the delayed onset of high-affinity antibody responses mediated by HLA-II products. On the other hand, *HLA-DRB1\*13:03* is in moderate LD with *HLA-B\*57*, but its association with low VL remained clear even when patients with *HLA-B\*57* were excluded \[[@B41-viruses-04-02080]\].

When the mature HLA-B protein forms are inferred from *HLA-B* genotyping results, three amino acid residues at positions 67, 70, and 97 (Met^67^, Ser^70^ and Val^97^around the C and F pockets) seem to explain alleles (e.g.; B\*57) associated with favorable outcomes (HIV-1 control) \[[@B42-viruses-04-02080]\].
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###### 

Host Genetic Factors That Are Positively or Negatively Associated with HIV-1 Viral Load (VL) Set-Point or Assumed Set-point, as Reported in Recent Studies.^a^

  Gene or gene cluster^b^                                    Allele or haplotype^c^                      Ethnicity^d^           Impact on VL                                                                                                                                                                  Refs
  ---------------------------------------------------------- ------------------------------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  Classical HLA class I genes: *HLA-A, HLA-B*, and *HLA-C*   **A\*32**                                   AA                     Favorable                                                                                                                                                                     \[[@B35-viruses-04-02080]\]
  **A\*36**                                                  African                                     Unfavorable            \[[@B34-viruses-04-02080], [@B35-viruses-04-02080]\]                                                                                                                          
  **A\*74**                                                  AA, African                                 Favorable              \[[@B33-viruses-04-02080],[@B34-viruses-04-02080],[@B35-viruses-04-02080],[@B39-viruses-04-02080]\]                                                                           
  **B\*13**                                                  African                                     Favorable              \[[@B34-viruses-04-02080]\]                                                                                                                                                   
  B\*14                                                      AA                                          Favorable              \[[@B35-viruses-04-02080]\]                                                                                                                                                   
  B\*18                                                      African                                     Unfavorable            \[[@B33-viruses-04-02080]\]                                                                                                                                                   
  **B\*27**                                                  Caucasian                                   Favorable              \[[@B32-viruses-04-02080]\]                                                                                                                                                   
  **B\*35**                                                  Caucasian                                   Unfavorable            \[[@B32-viruses-04-02080],[@B35-viruses-04-02080]\]                                                                                                                           
  B\*44                                                      African                                     Favorable              \[[@B36-viruses-04-02080]\]                                                                                                                                                   
  **B\*45**                                                  AA, African                                 Unfavorable            \[[@B34-viruses-04-02080],[@B35-viruses-04-02080]\]                                                                                                                           
  B\*53                                                      AA                                          Unfavorable            \[[@B35-viruses-04-02080]\]                                                                                                                                                   
  **B\*57**                                                  AA, African, Caucasian                      Favorable              \[[@B32-viruses-04-02080],[@B33-viruses-04-02080],[@B34-viruses-04-02080],[@B35-viruses-04-02080],[@B36-viruses-04-02080],[@B39-viruses-04-02080],[@B43-viruses-04-02080]\]   
  **B\*58:01**                                               African                                     Favorable              \[[@B33-viruses-04-02080],[@B43-viruses-04-02080]\]                                                                                                                           
  B\*58:02                                                   African                                     Unfavorable            \[[@B33-viruses-04-02080],[@B34-viruses-04-02080]\]                                                                                                                           
  **B\*81**                                                  African                                     Favorable              \[[@B34-viruses-04-02080]\]                                                                                                                                                   
  C\*08                                                      African                                     Favorable              \[[@B35-viruses-04-02080]\]                                                                                                                                                   
  **C\*18**                                                  African                                     Favorable              \[[@B34-viruses-04-02080],[@B35-viruses-04-02080]\]                                                                                                                           
  A\*30+C\*03                                                African                                     Favorable              \[[@B34-viruses-04-02080]\]                                                                                                                                                   
  C\*04:01-B\*81:01                                          African                                     Favorable              \[[@B33-viruses-04-02080]\]                                                                                                                                                   
  **C\*12-B\*39**                                            African                                     Favorable              \[[@B33-viruses-04-02080],[@B35-viruses-04-02080]\]                                                                                                                           
  Homozygosity                                               AA and African                              Unfavorable            \[[@B33-viruses-04-02080],[@B35-viruses-04-02080]\]                                                                                                                           
  *HLA-DRB1*                                                 DRB1\*01:02                                 African                Unfavorable                                                                                                                                                                   \[[@B34-viruses-04-02080]\]
  DRB1\*13:03                                                African                                     Favorable              \[[@B41-viruses-04-02080]\]                                                                                                                                                   
  Killer cell immunoglobulin-like receptor (KIR) genes       *KIR3DS1* copy no.                          Caucasian              Favorable if ≥1 copy                                                                                                                                                          \[[@B44-viruses-04-02080]\]
  *KIR3DL1* copy no.                                         Caucasian                                   Favorable if ≥1 copy   \[[@B44-viruses-04-02080]\]                                                                                                                                                   
  *CCR5*                                                     **Δ32** heterozygosity                      Caucasian              Favorable                                                                                                                                                                     \[[@B45-viruses-04-02080]\]
  *CCR2-CCR5*                                                HHD/HHE                                     African                Unfavorable                                                                                                                                                                   \[[@B46-viruses-04-02080]\]
                                                             HHF\*2 homozygosity                         African                Favorable                                                                                                                                                                     \[[@B46-viruses-04-02080]\]
  *CCL3*                                                     rs5029410 allele C                          African                Favorable                                                                                                                                                                     \[[@B47-viruses-04-02080]\]
  *DC-SIGNR (CD209L)*                                        7 or 9 repeats of a 69-bp coding sequence   Asian (Chinese)        Unfavorable                                                                                                                                                                   \[[@B48-viruses-04-02080]\]
  Miscellaneous loci (sporadic SNPs)                         rs2395029, allele C                         Caucasian              Favorable                                                                                                                                                                     \[[@B45-viruses-04-02080],[@B49-viruses-04-02080]\]
  rs9264942, allele G                                        Caucasian                                   Favorable              \[[@B45-viruses-04-02080],[@B49-viruses-04-02080]\]                                                                                                                           

^a^ Four studies \[[@B50-viruses-04-02080],[@B51-viruses-04-02080],[@B52-viruses-04-02080],[@B53-viruses-04-02080]\] with mostly negative results (not reaching statistical significance) are cited briefly in the text.

^b^ Organized by group and sorted by degree of popularity, *i.e.*; the number of studies meeting criteria (see [Figure 1](#viruses-04-02080-f001){ref-type="fig"}).

^c^ **Variants in bold** have shown consistency between studies conducted by different investigators. Certain amino acid residues may account for *HLA-B* allelic effects (e.g.; B\*57 and B\*81) \[[@B42-viruses-04-02080],[@B54-viruses-04-02080]\], as discussed in the text.

^d^ AA=African American.

In African Americans, nonsynonymous single nucleotide polymorphism (SNPs) corresponding to HLA-B amino acid positions 63, 97, and 116 account for much of the effects attributable to the *HLA-B* locus \[[@B54-viruses-04-02080]\]. However, *HLA-B\*44* alleles (Ser^67^, Asn^70^ and Arg^97^) that are favorable in native Africans did not conform to this newly recognized rule \[[@B36-viruses-04-02080]\]. Similarity or difference in peptide-binding preferences alone may not fully capture the spectrum of concerted and evolving immune function that is essential to durable containment of HIV-1 infection \[[@B55-viruses-04-02080]\].

Specific alleles and codon positions aside, HLA-I homozygosity (lack of diversity) has what appears to be an additive effect on set-point VL \[[@B33-viruses-04-02080],[@B35-viruses-04-02080]\] ([Table 1](#viruses-04-02080-t001){ref-type="table"}), probably by allowing rapid viral immune escape. Homozygosity is mostly restricted to common HLA-I alleles found in a given population, so its disadvantage may alternatively imply the advantage of rare or infrequent alleles to which viral adaptation is less likely to occur \[[@B56-viruses-04-02080]\]. This concept of allele frequency-dependent influences on HIV-1 pathogenesis deserves further evaluation \[[@B35-viruses-04-02080],[@B38-viruses-04-02080]\].

2.2 Killer Cell Immunoglobulin-like Receptor (KIR) Genes
--------------------------------------------------------

KIR gene products are primarily expressed on natural killer (NK) cells to inhibit or activate cytotoxic activities, depending on the combination of receptor-ligand (HLA-B or HLA-C) pairing \[[@B53-viruses-04-02080],[@B57-viruses-04-02080],[@B58-viruses-04-02080]\]. Just like their HLA ligands, KIR molecules are highly polymorphic in terms of gene content and allelic diversity. In the presence of HLA-B ligand Bw4-80I, the activating KIR3DS1 and inhibitory KIR3DL1 may delay HIV-1 disease progression (time to AIDS or death) \[[@B57-viruses-04-02080],[@B59-viruses-04-02080]\]. The specific role of KIR-HLA interaction in the early course of HIV-1 infection is not obvious \[[@B60-viruses-04-02080]\].

New evidence now suggests that *KIR3DS1* copy number variation is worth noting ([Table 1](#viruses-04-02080-t001){ref-type="table"}). When HLA-Bw4-80I is present, one or more copies of *KIR3DS1* was associated with relatively low set-point VL even after statistical adjustments for other known factors in the KIR-HLA interaction pathway, including *HLA-B\*57*, *B\*27*, and *B\*35Px* \[[@B44-viruses-04-02080]\]. Two other recent studies found no association between *KIR3DL1*, *KIR3DS1,* or *KIR2DS4* and viral load \[[@B52-viruses-04-02080],[@B53-viruses-04-02080]\]. Differences in methodology and *KIR3DS1* population frequencies may account for the lack of immediate consensus.

2.3 Chemokine Receptors and Ligand Genes
----------------------------------------

Several chemokine receptors, especially CCR5 and CCR2, act as HIV-1 co-receptors that facilitate viral entry into target cells. Neighboring *CCR2* and *CCR5* gene variants (haplotypes and diplotypes) have well-known relationships to HIV-1 transmission (initiation of infection) \[[@B61-viruses-04-02080]\], but their role in established infection is not persuasive \[[@B25-viruses-04-02080],[@B62-viruses-04-02080]\]. Heterozygosity for the 32-base-pair deletion in the *CCR5* gene open reading frame is of epidemiological importance to various populations \[[@B62-viruses-04-02080],[@B63-viruses-04-02080],[@B64-viruses-04-02080],[@B65-viruses-04-02080]\], so is the amino acid substitution of valine to isoleucine at CCR2 residue 64 (64V/I). The *CCR2-CCR5* haplotypes tagged by *CCR5-Δ32* (HHG\*2) and *CCR2-64I* (HHF\*2) may act in concert to influence set-point VL in populations of European ancestry \[[@B62-viruses-04-02080]\], but that combination (HHF\*2/HHG\*2) is too rare in other racial groups to be a worthy topic. Further work on various genes encoding CCR5 ligands (MIP-1α, MIP-1β, and CCL5/RANTES) often leads to inconsistent or conflicting observations \[[@B66-viruses-04-02080]\].

Investigation of chemokine receptor and ligand genes is still active ([Table 1](#viruses-04-02080-t001){ref-type="table"}). Translation of *CCR5-Δ32* to low set-point VL has gained new supporting evidence \[[@B45-viruses-04-02080]\]. Modest advantage was also seen with HHF\*2 homozygosity \[[@B46-viruses-04-02080]\]. The HHD/HHE diplotype commonly seen in cohorts of African ancestry appeared to be unfavorable \[[@B46-viruses-04-02080]\]. More recently, the minor allele C for SNP rs5029410 (in the *CCL3* gene) has been associated with low set-point VL \[[@B47-viruses-04-02080]\], with a low probability of false discovery from multiple testing.

2.4 Other Miscellaneous Observations Based on Candidate Gene Approach
---------------------------------------------------------------------

One study has revealed that *DC-SIGNR* (*CD209L*) genotypes can be associated with HIV-1 VL: the alleles encoding 7-repeat and 9-repeat isoforms appear to be unfavorable \[[@B48-viruses-04-02080]\] ([Table 1](#viruses-04-02080-t001){ref-type="table"}). The number of 23-amino acid repeats in the DC-SIGNR protein ranges from three to nine \[[@B67-viruses-04-02080]\], and the reported associations can be attributed to two isoform combinations, 5/7 and 7/9. Biologically, DC-SIGNR and DC-SIGN are transmembrane receptors on dendritic cells that help ferry HIV-1 virions to tissues enriched with CD4^+^ T-cells \[[@B68-viruses-04-02080]\]. Earlier work has shown some evidence about a possible distinction between the seven- or nine-repeat isoforms and others \[[@B67-viruses-04-02080]\].

2.5 Results From Genome-wide Association Studies (GWAS)
-------------------------------------------------------

GWAS provide a hypothesis-free approach to identifying genes or SNPs of epidemiological importance. Multiple GWAS have consistently pointed to two SNPs as markers of effective immune control during HIV-1 infection. The first, rs2395029, is mapped to the *HCP5* pseudogene. The second, rs9264942, is located about 35-kb upstream of *HLA-C* \[[@B69-viruses-04-02080],[@B70-viruses-04-02080],[@B71-viruses-04-02080],[@B72-viruses-04-02080],[@B73-viruses-04-02080],[@B74-viruses-04-02080],[@B75-viruses-04-02080],[@B76-viruses-04-02080]\]. In Caucasians, these SNPs effectively tag *HLA-B\*57:01* and a microRNA target site polymorphism in *HLA-C* 3' untranslated region (UTR), respectively \[[@B69-viruses-04-02080],[@B77-viruses-04-02080]\]. Other HLA-I alleles can be involved as well \[[@B71-viruses-04-02080],[@B72-viruses-04-02080],[@B78-viruses-04-02080],[@B79-viruses-04-02080]\].

Variants defined by rs2395029 and rs9264942 are highlighted in two new studies \[[@B45-viruses-04-02080],[@B49-viruses-04-02080]\] ([Table 1](#viruses-04-02080-t001){ref-type="table"}). Separate analysis of SCs and SPs is considered useful as the effect sizes for many individual SNPs can vary greatly between SCs and SPs \[[@B49-viruses-04-02080]\]. Two other GWAS based on African-Americans and native Africans failed to identify any SNPs with genome-wide statistical significance \[[@B50-viruses-04-02080],[@B51-viruses-04-02080]\]. In the African-American cohort, the top 10 SNPs of interest are all within the human major histocompatibility complex (MHC) \[[@B50-viruses-04-02080]\]. The SNP (rs2523608) with the best association signal ([Table 1](#viruses-04-02080-t001){ref-type="table"}) is actually in LD with *HLA-B\*57:03* (a favorable allele). In analysis of native Africans \[[@B51-viruses-04-02080]\], the number one SNP of interest (rs13111989) is beyond the MHC region ([Table 1](#viruses-04-02080-t001){ref-type="table"}).

3. Viral Genetics and HIV-1 Set-point VL
========================================

3.1 HIV-1 Genotype
------------------

Epidemiologists and virologists are acutely aware of the evidence that defective viruses might partially explain spontaneous HIV-1 control, as seen in the strings of patients infected by a single blood donor in Sydney, Australia \[[@B80-viruses-04-02080],[@B81-viruses-04-02080]\]. The ability of such viruses to cause sexual transmission (an inefficient process) is unclear, but recent analyses of 134 native Africans with sexually transmitted primary HIV-1 infection \[[@B36-viruses-04-02080]\] did reveal that acute-phase VL can be low (\<2,000 copies/mL) in a small proportion (\~6.7%) of SCs. Direct experimental evidence is still elusive as infectious viruses are hard to recover from these subjects. Conversely, however, SCs with set-point VL below 50 copies/mL can have measurable acute-phase VL (\>10,000 copies/mL) \[[@B36-viruses-04-02080]\]. Other investigators have also come across rare cases where elite control was possible even when highly pathogenic viruses from clinical AIDS patients were transmitted \[[@B82-viruses-04-02080]\].
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###### 

Viral Markers That Are Associated with HIV-1 Set-Point Viral Load (VL), as Reported in Recent Studies.

  Viral factor                            Measurement                                                         Impact on set-point VL                                     Refs
  --------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------- -----------------------------
  Heritability                            Transmission source partner (TSP) VL                                TSP VL correlates with set-point VL in linked recipients   \[[@B83-viruses-04-02080]\]
  Genetic distance on phylogenetic tree   High heritability in set-point VL, from one infection to the next   \[[@B84-viruses-04-02080]\]                                

Following and verifying HIV-1 transmission chains are not easily done, but the assessment of donor and recipient VL can be useful \[[@B85-viruses-04-02080]\]. New results from analyses of linked transmission pairs ([Table 2](#viruses-04-02080-t002){ref-type="table"}) support a modest linear relationship between donor VL (chronic) and recipient set-point VL \[[@B83-viruses-04-02080]\]. In a second study, genetic distances between viral sequences correlate with differences in VL \[[@B84-viruses-04-02080]\], suggesting that viral genotypes should be considered during the search for quantitative trait loci.

3.2 Interaction of Host and Viral Genetic Factors
-------------------------------------------------

To properly dissect out factors (host or viral) with the greatest influence on HIV-1 evolution and viral load, models will need to simultaneously consider host and viral dynamics \[[@B83-viruses-04-02080],[@B85-viruses-04-02080],[@B86-viruses-04-02080]\]. Among three closely related *HLA-B* allelic products examined in this context \[[@B43-viruses-04-02080]\], HLA-B\*57:03 appears to target four p24 Gag epitopes (ISW9, KF11, TW10, and QW9), but HLA-B\*57:02 and HLA-B\*58:01 only target three and two of them, respectively \[[@B43-viruses-04-02080]\]. Conceivably, these allelic forms can impose differential selection pressure on the viral genome. In the end, the causal factors of viral fitness can lie in the host and in the transmitted virus.

4. Methodological Challenges
============================

4.1 Variations in Calculation of Set-point VL
---------------------------------------------

Despite its wide use, there is still no standard method for determining HIV-1 set-point VL, with multiple methods having been used rather randomly \[[@B87-viruses-04-02080]\]. When a single RNA measurement is treated as the set-point \[[@B16-viruses-04-02080],[@B71-viruses-04-02080],[@B88-viruses-04-02080]\], the timing of such measurement can vary greatly: (i) the visit after the first seropositive visit, (ii) visit at least three months after the estimated date of infection (EDI), (iii) visit at least six months after the EDI. Others prefer to use data from several visits \[[@B12-viruses-04-02080],[@B89-viruses-04-02080]\], in favor of methods that calculate the VL phenotype as the average or as the median of multiple VL points within specific intervals of infection \[[@B87-viruses-04-02080]\]. Those with more advanced statistical skills simply test repeated VL measurements in mixed models \[[@B36-viruses-04-02080],[@B78-viruses-04-02080]\], but asymmetry in data structure (total visits and visit intervals) can be an issue. Decision to exclude patients with insufficient data can be a sticky business.

4.2 Early Chronic Phase *Versus* Chronic Phase
----------------------------------------------

Viral adaptation to the host microenvironment, including protective immune responses, is a gradual process. VLs taken during the early and later course of infection can possess similar traits for very different reasons \[[@B24-viruses-04-02080],[@B34-viruses-04-02080],[@B49-viruses-04-02080]\], so findings are not directly comparable when the duration of infection is unknown. As most studies have already missed the early course of infection \[[@B65-viruses-04-02080]\], the literature is likely most relevant to chronic infection when opportunistic infections (OIs) may complicate the analysis \[[@B33-viruses-04-02080],[@B34-viruses-04-02080],[@B35-viruses-04-02080]\]. The OIs can be disparate in exposure, tissue compartments, and geography, but they are rarely captured in analysis of HIV-1 VL readouts.

4.3 Changes in Set-point VL over Calendar Time
----------------------------------------------

Several studies have noted an increase in set-point VL over time \[[@B45-viruses-04-02080],[@B90-viruses-04-02080],[@B91-viruses-04-02080],[@B92-viruses-04-02080]\], while others disagree \[[@B93-viruses-04-02080],[@B94-viruses-04-02080],[@B95-viruses-04-02080]\]. A large meta-analysis pooling results from prior studies of seroincident patients found a trend for a rising VL set-point over time \[[@B96-viruses-04-02080]\]. Assuming that widespread viral adaptation does occur \[[@B45-viruses-04-02080],[@B96-viruses-04-02080],[@B97-viruses-04-02080]\], one can envision that the timing of the AIDS epidemic in different populations can be critical. In an European population, pre-2003 set-point VL appeared to differ from post-2003 VL in SCs \[[@B91-viruses-04-02080]\], accompanied by a loss of host genetic advantage conferred by *CCR5-Δ32* and other prominent factors (e.g.; rs2395029/*B\*57:01*) \[[@B45-viruses-04-02080]\]. Likewise, patients with *HLA-B\*51* before and after 2001 differed in their VLs \[[@B98-viruses-04-02080]\], which is consistent with the hypothesis that specific CTL escape mutations induced by HLA-mediated immunity can reach fixation when these mutations have no apparent fitness costs \[[@B99-viruses-04-02080]\]. Finding the tipping point for adapted *versus* unadapted viruses in each population is obviously another sticky business.

4.4 Other Potential Confounders
-------------------------------

Cofactors not routinely considered in analysis of HIV-1 VL can be quite obvious. For example, age and gender are known to influence VL \[[@B37-viruses-04-02080]\], but they are infrequently seen in reported statistical models. Other less obvious factors can range from viral subtypes and its segregation with certain racial backgrounds \[[@B100-viruses-04-02080],[@B101-viruses-04-02080]\] to differential distribution of important genetic variations (e.g.; *CCR5-Δ32* and *HLA-B\*27*) or the techniques used for defining them. Future studies will clearly need to apply multivariable models to carefully consider covariates and potential confounders. Composite scores based on all known factors may offer a temporary solution to simplifying the data analysis process \[[@B13-viruses-04-02080],[@B102-viruses-04-02080]\], although individual factors may not have equally additive effects on HIV-1 VL.

5. Conclusions
==============

HIV-1 viremia is an informative quantitative trait that varies at the individual and population levels. While many studies have attempted to sort out the quantitative trait loci, lack of clear consensus hints at various problems with study design and data analysis.

Factors important to VL can lie in the host and viral genomes. As viral evolution shaped by host immune responses become more and more predictable, fine-mapping of viral and host genetics can begin to allow a fair assessment of primary and secondary factors for transformative research. In other words, an open-minded research question is not whether host factors predominate over viral factors or vice versa, the two are so intertwined that their constant interactions in distinct individuals and populations collectively dictate the landscape of viral dynamics. The ultimate challenge (and goal) is to properly integrate comprehensive data on host and viral characteristics. The need for such approach is urgent, as datasets generated by high-throughput techniques will become overwhelmingly complex.
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